---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-042483"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2026-09-14T12:00:18+00:00"
generated_at: "2026-09-14T12:05:40.715182+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Telomir announces preclinical osteosarcoma data: Telomir-Zn inhibits growth in human and canine cell lines

## Summary
- Ohio State study: Telomir-Zn inhibited growth in HOS (human), D17 (canine), and Abrams (canine) osteosarcoma cell lines at similar low drug concentrations.
- Company assessing potential in vivo canine osteosarcoma efficacy study with Ohio State; TNBC Phase 1/2 enrollment advancing toward site initiation.
- Lead investigator Shay Bracha, DVM, DACVIM (Oncology); findings support translational development in both veterinary and human osteosarcoma.
- TNBC program remains immediate focus under active FDA-cleared IND; osteosarcoma is a parallel Track 2 development pathway.

## SEC filing metadata
- accession: 0001493152-26-042483
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2026-09-14T12:00:18+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315226042483/0001493152-26-042483-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315226042483/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-042483
- JSON: https://secwatch.observer/filing/0001493152-26-042483.json
- Plain text: https://secwatch.observer/filing/0001493152-26-042483.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.